Related Experiment Video
Updated: Apr 28, 2026
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
First-line therapeutic options for advanced non-small-cell lung cancer in the molecular medicine era
Enrica Capelletto1, Silvia Novello, Giorgio V Scagliotti
1Department of Oncology, University of Turin, San Luigi Hospital, Regione Gonzole 10, 10043 Orbassano (Torino), Italy.
Abstract:
Lung cancer is the leading cause of cancer-related mortality worldwide in both sexes, expected to account, in the near future, for more than 30% of all cancer-related deaths. Recently, improvements in the systemic therapy of non-small-cell lung cancer according to histology and tumor molecular characteristics led to a progressive prolongation of survival, more clinically meaningful in selected groups of patients with tumors harboring specific genomic alterations. As the search for individualized therapeutic approaches could represent one of the potential ways to improve survival expectancy of non-small-cell lung cancer patients with advanced disease stage, the aim of this review is to discuss how currently to select the best front-line therapeutic strategy.
Insights
Lung cancer remains a leading cause of death globally. Personalized treatment strategies for non-small-cell lung cancer, based on tumor genetics, are improving patient survival, especially in advanced stages.
Area of Science:
- Oncology
- Genomics
- Medical Treatment
Background:
- Lung cancer is the primary cause of cancer mortality worldwide.
- Non-small-cell lung cancer (NSCLC) survival has improved with targeted therapies.
- Tumor molecular characteristics are key to effective treatment selection.
Purpose of the Study:
- To review current strategies for selecting first-line therapy in advanced NSCLC.
- To highlight the importance of individualized treatment approaches.
- To discuss the role of genomic alterations in treatment decisions.
Main Methods:
- Literature review of recent advancements in NSCLC systemic therapy.
- Analysis of treatment selection based on histology and molecular profiling.
- Discussion of individualized therapeutic strategies for advanced NSCLC.
Main Results:
- Systemic therapy improvements have prolonged survival in NSCLC patients.
- Patients with specific genomic alterations show significant survival benefits.
- Histology and molecular characteristics guide effective front-line treatment selection.
Conclusions:
- Individualized therapeutic approaches are crucial for improving NSCLC survival.
- Selecting front-line therapy based on tumor genomics is a promising strategy.
- Further research into personalized medicine for advanced NSCLC is warranted.
More Related Videos
05:17Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
02:18Cancer